Lupin gets USFDA nod for generic equivalent of Kerydin Topical Solution
Mumbai, Baltimore: Global pharma major, Lupin Limited, has recently announced that the company has received approval for its Tavaborole Topical Solution, 5%, from the United States Food and Drug Administration (USFDA).
The product is a generic equivalent of Kerydin Topical Solution, 5%, of Anacor Pharmaceuticals, Inc.
The product will be manufactured at Lupin's facility in Pithampur, India.
Tavaborole Topical Solution, 5%, is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Tavaborole Topical Solution (RLD: Kerydin) had estimated annual sales of USD 76 million in the U.S. (IQVIA MAT December 2020).
Read also: Lupin inks pact with Phil for bacterial vaginosis drug Solosec
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd